The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany
Stefan Scholz(Robert Koch Institute), Wolfgang Greiner(Bielefeld University), R Welte(GlaxoSmithKline (Germany)), Kinga Meszaros(GlaxoSmithKline (Belgium)), Florian Koerber(MorphoSys (Germany)), B. Ultsch(Robert Koch Institute), Rosa Maya Fassbender(MorphoSys (Germany))
Cited by 29
Related Papers
Barriers and Strategies in Guideline Implementation—A Scoping Review
|Healthcare|2016|946
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
German Value Set for the EQ-5D-5L
|PharmacoEconomics|2018|618
Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study
|Quality of Life Research|2010|476
A single European currency for EQ-5D health states
|The European Journal of Health Economics|2003|465